Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Diagnostic Professionals, Inc
mi
from
Plantation, FL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Diagnostic Professionals, Inc
mi
from
Plantation, FL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Southeastern Resarch Group, Inc.
mi
from
Tallahassee, FL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Southeastern Resarch Group, Inc.
mi
from
Tallahassee, FL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Peachtree Hematology-Oncology Consultants
mi
from
Atlanta, GA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Peachtree Hematology-Oncology Consultants
mi
from
Atlanta, GA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
St. Alphonsus Regional Medical Center
mi
from
Boise, ID
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
St. Alphonsus Regional Medical Center
mi
from
Boise, ID
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
North Idaho Urology
mi
from
Coeur d'Alene, ID
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
North Idaho Urology
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Idaho Urologic Institute, P.A.
mi
from
Meridian, ID
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Idaho Urologic Institute, P.A.
mi
from
Meridian, ID
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
North Idaho Urology
mi
from
Sandpoint, ID
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
North Idaho Urology
mi
from
Sandpoint, ID
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
University of Chicago
mi
from
Chicago, IL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Evanston Northwestern Healthcare
mi
from
Evanston, IL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Evanston Northwestern Healthcare
mi
from
Evanston, IL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Galesburg Cottage Hospital
mi
from
Galesburg, IL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
OSF St Mary Medical Center
mi
from
Galesburg, IL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
OSF St Mary Medical Center
mi
from
Galesburg, IL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Midwest Urology/RMD Clinical Research Institute
mi
from
Melrose Park, IL
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Midwest Urology/RMD Clinical Research Institute
mi
from
Melrose Park, IL
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Johns Hopkins
mi
from
Baltimore, MD
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
AdvanceMed Research
mi
from
Lawrenceville, NJ
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
AdvanceMed Research
mi
from
Lawrenceville, NJ
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Urology Group of New Mexico
mi
from
Albuquerque, NM
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Urology Group of New Mexico
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Community Care Physicians, PC / The Urological Institute of Northeastern New York
mi
from
Albany, NY
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Community Care Physicians, PC / The Urological Institute of Northeastern New York
mi
from
Albany, NY
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Beth Israel Med Ctr
mi
from
New York, NY
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Beth Israel Med Ctr
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
University Urological Associates
mi
from
New York, NY
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
University Urological Associates
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Staten Island Urological Research, PC
mi
from
Staten Island, NY
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Staten Island Urological Research, PC
mi
from
Staten Island, NY
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Wake Urological Associates
mi
from
Raleigh, NC
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Wake Urological Associates
mi
from
Raleigh, NC
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Urologic Consultants of SE PA
mi
from
Bala Cynwyd, PA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Urologic Consultants of SE PA
mi
from
Bala Cynwyd, PA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Center for Urologic Care of the Main Line
mi
from
Bryn Mawr, PA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Center for Urologic Care of the Main Line
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Urological Associates of Lancaster
mi
from
Lancaster, PA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Urological Associates of Lancaster
mi
from
Lancaster, PA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
University of Pittsburgh Physicians, Department of Urology
mi
from
Pittsburgh, PA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
University of Pittsburgh Physicians, Department of Urology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Vanderbilt University Medical Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Virginia Oncology Associates
mi
from
Hampton, VA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Virginia Oncology Associates
mi
from
Hampton, VA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Virginia Oncology Associates
mi
from
Newport News, VA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Virginia Oncology Associates
mi
from
Newport News, VA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Virginia Oncology Associates
mi
from
Norfolk, VA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Virginia Oncology Associates
mi
from
Norfolk, VA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Seattle Urology Research Center
mi
from
Burien, WA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Seattle Urology Research Center
mi
from
Burien, WA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Roger D. Fincher, PS
mi
from
Spokane, WA
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Roger D. Fincher, PS
mi
from
Spokane, WA
Click here to add this to my saved trials
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
Andreou Research
mi
from
Surrey,
Efficacy Study of ABR-215050 to Treat Prostate Cancer
Phase II Randomized Double Blind Placebo-Controlled Study to Determine the Efficacy of ABR-215050 in Asymptomatic Patients With Metastatic Castrate-Resistant Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
Andreou Research
mi
from
Surrey,
Click here to add this to my saved trials
Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
A Phase II Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for the Treatment of Patients With Evidence of Serologic (PSA) Progression After Definitive Therapy for Localized Prostate Cancer
Status: Enrolling
Updated:  10/2/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for Patients With Rising Prostate-Specific Antigen (PSA)
A Phase II Study of Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) for the Treatment of Patients With Evidence of Serologic (PSA) Progression After Definitive Therapy for Localized Prostate Cancer
Status: Enrolling
Updated: 10/2/2015
UCSF Helen Diller Family Comprehensive Cancer Center
mi
from
San Francisco, CA
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Georgetown University Medical Center
mi
from
Washington,
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
University of Chicago Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Oncology Specialists, SC
mi
from
Park Ridge, IL
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Oncology Specialists, SC
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Indiana University Department of Urology
mi
from
Indianapolis, IN
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Indiana University Department of Urology
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Maine Center for Cancer Medicine
mi
from
Scarborough, ME
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Maine Center for Cancer Medicine
mi
from
Scarborough, ME
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Hematology Oncology Consultants
mi
from
Greenbelt, MD
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Hematology Oncology Consultants
mi
from
Greenbelt, MD
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Myron I Murdock MD LLC
mi
from
Greenbelt, MD
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Myron I Murdock MD LLC
mi
from
Greenbelt, MD
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
NYU Cancer Institute
mi
from
New York, NY
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
NYU Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Mount Sinai School of Medicine Department of Urology
mi
from
New York, NY
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Mount Sinai School of Medicine Department of Urology
mi
from
New York, NY
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Columbia University Medical Center
mi
from
New York, NY
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Columbia University Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
GU Oncology Research Program
mi
from
Durham, NC
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
GU Oncology Research Program
mi
from
Durham, NC
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Texas Oncology Sammons Cancer Center
mi
from
Dallas, TX
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Texas Oncology Sammons Cancer Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated:  10/5/2015
Urology of Virginia/ Sentara
mi
from
Norfolk, VA
Open Label Study of Sipuleucel-T
An Open Label Study of Sipuleucel-T in Men With Metastatic Castrate Resistant Prostate Cancer
Status: Enrolling
Updated: 10/5/2015
Urology of Virginia/ Sentara
mi
from
Norfolk, VA
Click here to add this to my saved trials